Skip to content
Clinical Trials – home

Universitaetsklinikum Duesseldorf AöR

Verified siteinfo

Germany Moorenstrasse 5, Bilk, 40225 Duesseldorf, Germany

  • 142 trials recruiting
  • Breast cancer · Acute myeloid leukaemia · Cholangiocarcinoma
  • Adults and children

About Specializations

Universitaetsklinikum Duesseldorf AöR in Duesseldorf, Germany specialises in clinical trials of conditions such as Breast cancer, Acute myeloid leukaemia, Cholangiocarcinoma, Acute lymphocytic leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Research at Universitaetsklinikum Duesseldorf AöR

Clinical research at this hospital focuses on nervous system diseases, with a strong emphasis on multiple sclerosis and related neurological conditions. The studies are centered on understanding how new or emerging therapies may support long-term disease management and patient care.

  • Focus on neurology and broader nervous system diseases
  • Research in multiple sclerosis, including relapsing and progressive forms
  • Trials aimed at evaluating the safety and tolerability of treatment approaches

With 3 clinical trials and a large team of 76 investigators, the site contributes to ongoing efforts to improve treatment options and long-term outcomes for people living with neurological disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Moorenstrasse 5, Bilk40225 DuesseldorfGermany
Recruiting now
142 trials
Conditions studied
221
Partner status
Verified site

More sites in DuesseldorfGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

317 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Eli Lilly & Co.

Cold urticaria

Recruiting

A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of GSK5764227 alone and in combination for patients with previously treated advanced gastrointestinal tumors that cannot be removed by surgery or have spread

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.